Journal of Clinical Endocrinology & Metabolism, Vol 78, 513-522, Copyright © 1994 by Endocrine Society

ARTICLES

Characterization of mutant androgen receptors causing partial androgen insensitivity syndrome

A De Bellis, CA Quigley, KB Marschke, MK el-Awady, MV Lane, EP Smith, M Sar, EM Wilson and FS French
Department of Pediatrics, University of North Carolina, Chapel Hill 27599-7500.

The androgen insensitivity syndrome (AIS) is an X-linked disorder caused by mutations of the androgen receptor (AR) gene resulting in a spectrum of sex phenotypes that ranges from complete female (complete AIS) to nearly complete male (partial AIS). Using the polymerase chain reaction and denaturing gradient gel electrophoresis, we have analyzed the AR gene in three 46,XY individuals with partial AIS. In one subject whose androgen insensitivity was manifest at birth by clitoromegaly, posterior labial fusion, and a urogenital sinus, androgen-binding affinity in genital skin fibroblasts was similar to that of the control. In this subject, a mutation was identified in exon C encoding the second zinc finger of the androgen receptor. The mutation converted a leucine residue at position 616 to arginine, causing greatly reduced binding of receptor to an androgen-response element DNA sequence. However, the mutant AR retained a low level of transcriptional activity at physiological androgen concentrations in keeping with the subject's phenotype of partial AIS. In the second subject, who also had an ambiguous external genital phenotype, a single base mutation was identified in exon G, converting arginine at position 840 to histidine. Androgen-binding affinity in genital skin fibroblasts of this subject was 7-fold lower than control, and the mutant receptor had reduced transcriptional activity. In the third subject, who had a female phenotype with normal pubic hair reflecting a low degree of androgen responsiveness, the valine residue at position 889 was replaced by methionine. This mutant receptor had apparent normal androgen-binding affinity but reduced androgen-binding capacity when examined by expression of the recreated mutant AR in COS 7 cells. These results demonstrate the clinical, functional, and molecular heterogeneity in the syndrome of partial androgen insensitivity.

This article has been cited by other articles:

				R. Radpour, M. Falah, A. Aslani, X. Y. Zhong, and A. Saleki Identification of a Critical Novel Mutation in the Exon 1 of Androgen Receptor Gene in 2 Brothers With Complete Androgen Insensitivity Syndrome J Androl, May 1, 2009; 30(3): 230 - 232. [Abstract] [Full Text] [PDF]

				B. He, R. T. Gampe Jr., A. T. Hnat, J. L. Faggart, J. T. Minges, F. S. French, and E. M. Wilson Probing the Functional Link between Androgen Receptor Coactivator and Ligand-binding Sites in Prostate Cancer and Androgen Insensitivity J. Biol. Chem., March 10, 2006; 281(10): 6648 - 6663. [Abstract] [Full Text] [PDF]

				D.H. Abbott, D.K. Barnett, C.M. Bruns, and D.A. Dumesic Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum. Reprod. Update, July 1, 2005; 11(4): 357 - 374. [Abstract] [Full Text] [PDF]

				A. Umar, C. A. Berrevoets, N. M. Van, M. van Leeuwen, M. Verbiest, W. J. Kleijer, D. Dooijes, J. A. Grootegoed, S. L. S. Drop, and A. O. Brinkmann Functional Analysis of a Novel Androgen Receptor Mutation, Q902K, in an Individual with Partial Androgen Insensitivity J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 507 - 515. [Abstract] [Full Text] [PDF]

				S. E. Hannema, I. S. Scott, J. Hodapp, H. Martin, N. Coleman, J. W. Schwabe, and I. A. Hughes Residual Activity of Mutant Androgen Receptors Explains Wolffian Duct Development in the Complete Androgen Insensitivity Syndrome J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5815 - 5822. [Abstract] [Full Text] [PDF]

				B.-C. Jeong, C. Y. Hong, S. Chattopadhyay, J. H. Park, E.-Y. Gong, H.-J. Kim, S.-Y. Chun, and K. Lee Androgen Receptor Corepressor-19 kDa (ARR19), a Leucine-Rich Protein that Represses the Transcriptional Activity of Androgen Receptor through Recruitment of Histone Deacetylase Mol. Endocrinol., January 1, 2004; 18(1): 13 - 25. [Abstract] [Full Text] [PDF]

				C. Crescioli, M. Maggi, G. B. Vannelli, P. Ferruzzi, S. Granchi, R. Mancina, M. Muratori, G. Forti, M. Serio, and M. Luconi Expression of Functional Estrogen Receptors in Human Fetal Male External Genitalia J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1815 - 1824. [Abstract] [Full Text] [PDF]

				C. A. Heinlein and C. Chang Androgen Receptor (AR) Coregulators: An Overview Endocr. Rev., April 1, 2002; 23(2): 175 - 200. [Abstract] [Full Text] [PDF]

				C. Bouvattier, J.-C. Carel, C. Lecointre, A. David, C. Sultan, A.-M. Bertrand, Y. Morel, and J.-L. Chaussain Postnatal Changes of T, LH, and FSH in 46,XY Infants with Mutations in the AR Gene J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 29 - 32. [Abstract] [Full Text] [PDF]

				M. J. McPhaul Molecular Defects of the Androgen Receptor Recent Prog. Horm. Res., January 1, 2002; 57(1): 181 - 194. [Abstract] [Full Text] [PDF]

				B. He, J. A. Kemppainen, J. J. Voegel, H. Gronemeyer, and E. M. Wilson Activation Function 2 in the Human Androgen Receptor Ligand Binding Domain Mediates Interdomain Communication with the NH2-terminal Domain J. Biol. Chem., December 24, 1999; 274(52): 37219 - 37225. [Abstract] [Full Text] [PDF]

				M. J. McPhaul and J. E. Griffin Male Pseudohermaphroditism Caused by Mutations of the Human Androgen Receptor J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3435 - 3441. [Full Text] [PDF]

				S. Roux, B. Terouanne, B. Couette, M.-E. Rafestin-Oblin, and J.-C. Nicolas Conformational Change in the Human Glucocorticoid Receptor Induced by Ligand Binding Is Altered by Mutation of Isoleucine 747 by a Threonine J. Biol. Chem., April 9, 1999; 274(15): 10059 - 10065. [Abstract] [Full Text] [PDF]

				J. A. Kemppainen, E. Langley, C.-i. Wong, K. Bobseine, W. R. Kelce, and E. M. Wilson Distinguishing Androgen Receptor Agonists and Antagonists: Distinct Mechanisms of Activation by Medroxyprogesterone Acetate and Dihydrotestosterone Mol. Endocrinol., March 1, 1999; 13(3): 440 - 454. [Abstract] [Full Text]

				D. L. Shkolny, L. K. Beitel, J. Ginsberg, G. Pekeles, L. Arbour, L. Pinsky, and M. A. Trifiro Discordant Measures of Androgen-Binding Kinetics in Two Mutant Androgen Receptors Causing Mild or Partial Androgen Insensitivity, Respectively J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 805 - 810. [Abstract] [Full Text]

				Q. Wang, F. J. Ghadessy, A. Trounson, D. de Kretser, R. McLachlan, s. C. Ng, and E. L. Yong Azoospermia Associated with a Mutation in the Ligand-Binding Domain of an Androgen Receptor Displaying Normal Ligand Binding, but Defective Trans-Activation J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4303 - 4309. [Abstract] [Full Text]

				E. Langley, J. A. Kemppainen, and E. M. Wilson Intermolecular NH2-/Carboxyl-terminal Interactions in Androgen Receptor Dimerization Revealed by Mutations That Cause Androgen Insensitivity J. Biol. Chem., January 2, 1998; 273(1): 92 - 101. [Abstract] [Full Text] [PDF]

				B. He, J. A. Kemppainen, and E. M. Wilson FXXLF and WXXLF Sequences Mediate the NH2-terminal Interaction with the Ligand Binding Domain of the Androgen Receptor J. Biol. Chem., July 21, 2000; 275(30): 22986 - 22994. [Abstract] [Full Text] [PDF]